NCIC CTG MAP.3: Symptoms and quality of life (QoL) among racial/ethnic minority women taking the aromatase inhibitor (AI) exemestane (EXE) for breast cancer risk reduction.

摘要: 6557 Background: Racial/ethnic minority postmenopausal women reported fewer side effects than whites on the aromatase inhibitor (AI) letrozole in MA.17. We present symptoms and QoL according to race ethnicity taking EXE for BC prevention MAP.3. Methods: Adjusted proportions ever experiencing or reporting worsened SF-36 domains (change scores from baseline decreased by ≥ -5 points) among racial minorities (M) (W), Hispanics (H) non-Hispanics (non-H), were compared using logistic regression models adjusting age, body mass index (BMI), country, marital status, education level employment status. Results: Of 2285 randomized EXE, 2231 (97.6%) had information: 129 M (6.1%) 2102 W (93.9%).Compared W, significantly older, higher BMI, lower Gail scores, received more drugs cardiovascular diseases, likely live United States.M experienced sweats (12% vs. 22%; p = 0.005) less vagina...